358 related articles for article (PubMed ID: 25631837)
21. Sacral neuromodulation and Botulinum toxin A for refractory idiopathic overactive bladder: a cost-utility analysis in the perspective of Italian Healthcare System.
Bertapelle MP; Vottero M; Popolo GD; Mencarini M; Ostardo E; Spinelli M; Giannantoni A; D'Ausilio A
World J Urol; 2015 Aug; 33(8):1109-17. PubMed ID: 25218855
[TBL] [Abstract][Full Text] [Related]
22. AbobotulinumtoxinA (Dysport) dosing in cervical dystonia: an exploratory analysis of two large open-label extension studies.
Hauser RA; Truong D; Hubble J; Coleman C; Beffy JL; Chang S; Picaut P
J Neural Transm (Vienna); 2013 Feb; 120(2):299-307. PubMed ID: 22878514
[TBL] [Abstract][Full Text] [Related]
23. Clinical experience of dose conversion ratios between 2 botulinum toxin products in the treatment of cervical dystonia.
Rystedt A; Nyholm D; Naver H
Clin Neuropharmacol; 2012; 35(6):278-82. PubMed ID: 23123690
[TBL] [Abstract][Full Text] [Related]
24. Botulinum toxin therapy for cervical dystonia.
Jankovic J
Neurotox Res; 2006 Apr; 9(2-3):145-8. PubMed ID: 16785112
[TBL] [Abstract][Full Text] [Related]
25. A Retrospective, Single-Center Comparative Cost Analysis of OnabotulinumtoxinA and AbobotulinumtoxinA for Cervical Dystonia Treatment.
Trosch RM; Shillington AC; English ML; Marchese D
J Manag Care Spec Pharm; 2015 Oct; 21(10):854-60. PubMed ID: 26402386
[TBL] [Abstract][Full Text] [Related]
26. Xeomin in the treatment of cervical dystonia.
Benecke R
Eur J Neurol; 2009 Dec; 16 Suppl 2():6-10. PubMed ID: 20002740
[TBL] [Abstract][Full Text] [Related]
27. Retrospective evaluation of the dose of Dysport and BOTOX in the management of cervical dystonia and blepharospasm: the REAL DOSE study.
Marchetti A; Magar R; Findley L; Larsen JP; Pirtosek Z; Růzicka E; Jech R; Sławek J; Ahmed F
Mov Disord; 2005 Aug; 20(8):937-44. PubMed ID: 15810022
[TBL] [Abstract][Full Text] [Related]
28. A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia.
Odergren T; Hjaltason H; Kaakkola S; Solders G; Hanko J; Fehling C; Marttila RJ; Lundh H; Gedin S; Westergren I; Richardson A; Dott C; Cohen H
J Neurol Neurosurg Psychiatry; 1998 Jan; 64(1):6-12. PubMed ID: 9436720
[TBL] [Abstract][Full Text] [Related]
29. Botulinum toxin type A for the treatment of non-neurogenic overactive bladder: does using onabotulinumtoxinA (Botox(®) ) or abobotulinumtoxinA (Dysport(®) ) make a difference?
Ravindra P; Jackson BL; Parkinson RJ
BJU Int; 2013 Jul; 112(1):94-9. PubMed ID: 23490404
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of sacral neuromodulation versus intravesical botulinum A toxin for treatment of refractory urge incontinence.
Siddiqui NY; Amundsen CL; Visco AG; Myers ER; Wu JM
J Urol; 2009 Dec; 182(6):2799-804. PubMed ID: 19837427
[TBL] [Abstract][Full Text] [Related]
31. A long-term follow-up of botulinum toxin A in cervical dystonia.
Mohammadi B; Buhr N; Bigalke H; Krampfl K; Dengler R; Kollewe K
Neurol Res; 2009 Jun; 31(5):463-6. PubMed ID: 19278576
[TBL] [Abstract][Full Text] [Related]
32. Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice.
Scaglione F
Toxins (Basel); 2016 Mar; 8(3):. PubMed ID: 26959061
[TBL] [Abstract][Full Text] [Related]
33. The dystonia discomfort scale (DDS): a novel instrument to monitor the temporal profile of botulinum toxin therapy in cervical dystonia.
Dressler D; Kupsch A; Seitzinger A; Paus S
Eur J Neurol; 2014 Mar; 21(3):459-62. PubMed ID: 24433495
[TBL] [Abstract][Full Text] [Related]
34. [Treatment of focal dystonia with botulinum toxin A].
Sojer M; Wissel J; Müller J; Poewe W
Wien Klin Wochenschr; 2001; 113 Suppl 4():6-10. PubMed ID: 15506045
[TBL] [Abstract][Full Text] [Related]
35. A new botulinum toxin (Xeomin) for cervical dystonia and blepharospasm.
Med Lett Drugs Ther; 2010 Nov; 52(1351):90-1. PubMed ID: 21068703
[TBL] [Abstract][Full Text] [Related]
36. Estimating the cost-effectiveness of onabotulinumtoxinA for neurogenic detrusor overactivity in the United States.
Carlson JJ; Hansen RN; Dmochowski RR; Globe DR; Colayco DC; Sullivan SD
Clin Ther; 2013 Apr; 35(4):414-24. PubMed ID: 23522658
[TBL] [Abstract][Full Text] [Related]
37. Cost effectiveness and impact on quality of life of abobotulinumtoxinA and onabotulinumtoxinA in the treatment of children with lower limb spasticity in Canada.
Johnston K; Danchenko N; Hansen R; Dinet J; Liovas A; Armstrong A; Bains S; Sullivan SD
J Med Econ; 2020 Jun; 23(6):631-640. PubMed ID: 31985313
[No Abstract] [Full Text] [Related]
38. Cost-minimization analysis in the treatment of spasticity in children with cerebral palsy with botulinum toxin type A: an observational, longitudinal, retrospective study.
Tapias G; García-Romero M; Crespo C; Cuesta M; Forné C; Pascual-Pascual SI
Farm Hosp; 2016 Sep; 40(5):412-26. PubMed ID: 27570991
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetic properties of different formulations of botulinum neurotoxin type A.
Wohlfarth K; Kampe K; Bigalke H
Mov Disord; 2004 Mar; 19 Suppl 8():S65-7. PubMed ID: 15027057
[TBL] [Abstract][Full Text] [Related]
40. Five-year experience with incobotulinumtoxinA (Xeomin(®) ): the first botulinum toxin drug free of complexing proteins.
Dressler D
Eur J Neurol; 2012 Mar; 19(3):385-9. PubMed ID: 22035051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
